Fulcrum Therapeutics, Inc. SEC filings FULC
Fulcrum Therapeutics, Inc. has 520 filings in SEC EDGAR's recent list, going back to Jul 25, 2016. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Jul 30, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 17, 2026 (material agreement, unregistered share sale, change in control, officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | Nov 4, 2026 | — |
| S-4/A | Filing | Nov 3, 2026 | — |
| S-4/A | Filing | Oct 20, 2026 | — |
| S-4/A | Filing | Oct 8, 2026 | — |
| S-4 | Registration for a merger or exchange | Sep 2, 2026 | — |
| S-8 | Employee stock plan registration | Feb 24, 2026 | — |
| 424B5 | Prospectus supplement | Dec 11, 2025 | — |
| FWP | Free writing prospectus | Dec 10, 2025 | — |
| 424B5 | Prospectus supplement | Dec 8, 2025 | — |
| S-8 | Employee stock plan registration | Feb 25, 2025 | — |
| S-8 | Employee stock plan registration | Jul 31, 2024 | — |
| S-8 | Employee stock plan registration | Feb 27, 2024 | — |
| S-3 | Shelf registration | Feb 27, 2024 | — |
| S-8 | Employee stock plan registration | Mar 9, 2023 | — |
| 424B5 | Prospectus supplement | Jan 18, 2023 | — |
| 424B5 | Prospectus supplement | Jan 17, 2023 | — |
| 424B5 | Prospectus supplement | Aug 17, 2022 | — |
| 424B5 | Prospectus supplement | Aug 15, 2022 | — |
| 424B5 | Prospectus supplement | May 10, 2022 | — |
| POS AM | Filing | Mar 3, 2022 | — |
| S-8 | Employee stock plan registration | Mar 3, 2022 | — |
| S-8 | Employee stock plan registration | Jan 27, 2022 | — |
| S-3ASR | Automatic shelf registration | Nov 4, 2021 | — |
| 424B5 | Prospectus supplement | Aug 12, 2021 | — |
| S-3MEF | Filing | Aug 11, 2021 | — |
| 424B5 | Prospectus supplement | Aug 11, 2021 | — |
| S-8 | Employee stock plan registration | Mar 4, 2021 | — |
| 424B5 | Prospectus supplement | Jan 20, 2021 | — |
| 424B5 | Prospectus supplement | Jan 19, 2021 | — |
| POS AM | Filing | Aug 11, 2020 | — |
| S-3 | Shelf registration | Aug 11, 2020 | — |
| S-1 | Registration statement | Jun 22, 2020 | — |
| S-8 | Employee stock plan registration | Mar 5, 2020 | — |
| S-8 | Employee stock plan registration | Aug 26, 2019 | — |
| 424B4 | Prospectus | Jul 18, 2019 | — |
| S-1/A | Amended registration statement | Jul 12, 2019 | — |
| S-1/A | Amended registration statement | Jul 8, 2019 | — |
| S-1 | Registration statement | Jun 21, 2019 | — |
Showing 38 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FULC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1680581
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.